Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CDC42 | P60953 | 1/20 | 0.53 |
| ▸ | RAC1 | P63000 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535859 | 0.89 | PTGS2 (0.66) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL219579 | 0.83 | TDP1 (0.59) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL23969668 | 0.83 | TDP1 (0.59) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL2688602 | 0.81 | PTGS2 (0.52) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL5540261 | 0.81 | PTGS2 (0.54) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL5539984 | 0.81 | PTGS2 (0.54) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL2687772 | 0.79 | PTGS2 (0.57) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL14036827 | 0.79 | TDP1 (0.69) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL4692109 | 0.78 | AKR1C3 (0.61) | PTGS2PTGS1AKR1C3AKR1C2TSHR | |
| SCHEMBL577152 | 0.78 | PTGS2 (0.54) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S.A. (BR) | 2012-05-10 | — | — | US | disclosed |
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S.A. (BR) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | TNF, PER2, CRY1 | PTGS2 12/4885TDP1 4039/4885L3MBTL1 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.